• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Mid-Cycle Review Meeting Minutes, June 10, 2011 - Hemacord

 

Mid-Cycle Review Meeting Minutes
 
Sponsor:            New York Blood Center
BLA #: BLA 125397
Product:            Hematopoietic stem/progenitor cells, cord (HPC-C)
Date:                    June 10, 2011
Time:                    2:30PM -4:00PM
 
Meeting Attendees:   Thomas, Terrolyn; Witten, Celia; Bryan, Wilson; Przepiorka, Donna;; Nguyen, Loan; Stockbridge, Lisa L; Heidaran, Mohammad; Wang, Gang; Serabian, Mercedes; Hoque, Atm S.; Wonnacott, Keith; Quagraine, Mercy; Karandish, Safa; Wise, Robert; Riggins, Patrick; Puri, Raj K. Benton, Kimberly; Bross, Peter; Joshi, Bharat; Rees, Renee; Hyde, John E; Bauer, Steven; McCright, Brenton; Norwood, Laurie; Ghosh, Joydeep; Lazarus, Ellen;; Stevens, Ted; Bi, Lilia Lei; Witten, Rachel; Dapolito, Gail; Fan, Yong
 
 
1.   Introductions
 
2.    Important dates
 
Draft FDA Briefing Document
Due to Supervisors:                                   COB, July 8, 2011
 
Primary Reviews Due:                               COB, August 18, 2011
PDUFA GOAL Date:                     November 10, 2011
 
3.   Discipline Specific Reviews of Application (handouts provided)
  • CMC - M. Quagraine; B. McCright; B. Joshi; S, Bauer; J. Ghosh; S. Karandish
    Requested teleconference with sponsor to discuss outstanding issues.
  • DMPQ – M. Heidaran & G. Wang
    Requested teleconference with sponsor to discuss outstanding issues (483 citation update ; quality and batch record verification by August 1,2011).
  • ClinicalD. Przepiorka & J. Hyde
    Team will move forward with PeRc waiver. OCTGT Director, Dr Witten stated that OBE needs to review the data; OBE reviewer should be invited back to review team.
  • Labeling – L. Stockbridge & L. Nguyen
    Noted that mock package insert was sent to sponsor.
 
4.   Issues Requiring Resolution 
  • It was indicated that additional Malignancy and Metabolic Hematology Disease Specialist should be added to Advisory Committee panel.
  • DMPQ will review the DCGT recommendation on NYBC’s sample retention management for adequacy and update management
 
5.   Scheduled Meetings
  • Advisory Committee Meeting:   September 22, 2011
  • Wrap-UP Meeting:      October 6, 2011
  • Labeling Meeting: TBD
  • Team Meeting: June 21, 2011
  • Sponsor Meeting to Discuss Outstanding Issues: June 20, 2011